Veterinary Research Forum
Vet Res Forum

Suppression of the malignancy of mammary tumor in mice model by inactivated preparation of Mycobacterium obuense

Document Type : Original Article

Authors

Katayoon Nofouzi 1
Parsa Almasi 1
Ali Asghar Fakhri-Demeshgheieh 1
Monireh Khordadmehr 1
Behzad Baradaran 2
Milad Asadi 2
Parvin Sarbakhsh 3
Gholamreza Hamidian 4

1 Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran

2 Immunology Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

3 Department of Statics and Epidemiology, Faculty of Health Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

4 Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran

https://doi.org/10.30466/vrf.2021.525359.3144
Abstract
Breast cancer (BC) is a significant cause of global mortality in women. This study was aimed to evaluate the immune-activation of malignant BC via the administration of attenuated Mycobacterium obuense. For this purpose, an in vivo model was developed with BALB/c mice. Mice were injected with 2.00 × 106 4T1 cells with breast tumor cell line. Forty-two mice were equally divided into control as well as low dose (0.20 mg 100 µL-1) and high dose (0.50 mg 100 µL-1) groups of M. obuense to investigate gene expression in the antitumor effects of M. obuense. In one group, paclitaxel was administrated as a choice drug in BC treatment. Antitumor manners were characterized by cytotoxicity against tumor target cells, size of the tumor and the expression of some BC metastatic genes together with pathology. The MTT assay demonstrated that different concentrations of both low and a high doses of bacteria did present no cytotoxicity effect on 4T1 cells. According to our findings, M. obuense significantly repressed tumor growth. M. obuense downregulated the expression of collagen type I alpha 1 (COLIA1), cFos, alkaline phosphatase (ALP), claudin 3 (cldn3), and conversely, activated transcription factor 4 (ATF4) and Twist related protein-1 (Twist1). All these alternations induced a decrease in the migratory and invasive capabilities of BC. The result of pathology was indicative of tumor regression in the paclitaxel and HK- M. obuense -recipient group. Thus, it seems most likely that M. obuense might impinge upon cell growth and metastatic behavior of malignant cells exerting anti-tumor activity in BC.

Keywords

Breast cancer
Gene expression
Immunotherapy
Metastatic behavior
Mycobacterium obuense

  1.  

    1. Khordadmehr M, Shahbazi R, Ezzati H, et al. Key microRNAs in the biology of breast cancer; emerging evidence in the last decade. J Cell Physiol 2019; 234(6): 8316-8326.
    2. Ho BY, Lin CH, Apaya MK, et al. Silibinin and paclitaxel cotreatment significantly suppress the activity and lung metastasis of triple negative 4T1 mammary tumor cell in mice. J Tradit Complement Med 2012; 2(4): 301-311.
    3. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 2006; 66(7): 3347-3350.
    4. Fowler D, Dalgleish A, Liu W. A heat-killed preparation of mycobacterium obuense can reduce metastatic burden in vivo. J Immunother Cancer 2014; 2(Suppl 3): P54. doi: 10.1186/2051-1426-2-S3-P54.
    5. Bazzi S, Modjtahedi H, Mudan S, et al. Immuno-modulatory effects of heat-killed Mycobacterium obuense on human blood dendritic cells. Innate Immun 2017; 23(7): 592-605.
    6. Stebbing J, Dalgleish A, Gifford-Moore A, et al. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Ann Oncol 2012; 23(5): 1314-1319.
    7. Dalgleish AG, Stebbing J, Adamson DJ, et al. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer 2016; 115(7): 789-796.
    8. Fowler DW, Copier J, Wilson N, et al. Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother 2012; 61(4): 535-547.
    9. Wörmann SM, Diakopoulos KN, Lesina M, et al. The immune network in pancreatic cancer development and progression. Oncogene 2014; 33(23): 2956-2967.
    10. Ghazanchaei A, Mansoori B, Mohammadi A, et al. Restoration of miR‐152 expression suppresses cell proliferation, survival, and migration through inhibition of AKT–ERK pathway in colorectal cancer. J Cell Physiol 2019; 234(1): 769-776.
    11. Atiya HI, Dvorki-Gheva A, Hassell J, et al. Intraductal adoptation of 4T1 mouse model of breast cancer reveals effects of the epithelial microenvironment on tumor progression and metastasis. Anticancer Res 2019; 39(5): 2277-2287.
    12. Eralp Y, Wang X, Wang JP, et al. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 2004; 6(4): R275–R283.
    13. Kidner TB, Morton DL, Lee DJ, et al. Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 2012; 35(9): 716-720.
    14. Soliman H, Mediavilla-Varela M, Antonia SJ. A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model. Breast Cancer (Dove Med Press). 2015; 7: 389-397
    15. Toomey P, Kodumudi K, Weber A, et al. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PloS One 2013; 8: e68561. doi: 10.1371/journal.pone.0068561.
    16. Liu H, Innamarato PP, Kodumudi K, et al. Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget 2016; 7(25): 37893-37905.
    17. Rajeh MA, Kwan YP, Zakaria Z, et al. Acute toxicity impacts of Euphorbia hirta L extract on behavior, organs body weight index and histopathology of organs of the mice and Artemia salina. Pharmacognosy Res 2012; 4(3): 170-177.
    18. Zhang L, Wang Y, Zhang B, et al. Claudin-3 expression increases the malignant potential of lung adenocarci-noma cells: role of epidermal growth factor receptor activation. Oncotarget 2017; 8(14): 23033-23047.
    19. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003; 101(5): 1718-1726.
    20. Wang Q, Yu H, Zhang L, et al. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer. J Mol Med (Berl) 2002; 80(9): 585-594.
    21. Ansieau S, Morel AP, Hinkal G, et al. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 2010; 29: 3173-3184.
    22. Croset M, Goehrig D, Frackowiak A, et al. TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res 2014; 29(8): 1886-1899.
    23. Beck B, Lapouge G, Rorive S, et al. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 2015; 16(1): 67-79.
    24. Xu Y, Lee DK, Feng Z, et al. Breast tumor cell-specific knockout of Twist1 inhibits cancer cell plasticity, dissemination, and lung metastasis in mice. Proc Natl Acad Sci U S A 2017; 114(43): 11494-11499.
    25. Qin Q, Xu Y, He T, et al. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res 2012; 22(1): 90-106.
    26. Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adeno-carcinoma: association with angiogenesis and poor prognosis. Oncology 1999; 57(2): 138-142.
    27. Liu C, Li Z, Wang L, et al. Activating transcription factor 4 promotes angiogenesis of breast cancer through enhanced macrophage recruitment. BioMed Res Int 2015; 2015: 974615. doi:10.1155/2015/974615.
    28. Unni E, Kittrell FS, Singh U, et al. Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine. Breast Cancer Res 2004; 6(5): R586-R592.
    29. Wei R, Wong JPC, Kwok HF. Osteopontin--a promising biomarker for cancer therapy. J Cancer 2017; 8(12): 2173-2183.
    30. Bland KI, Konstadoulakis MM, Vezeridis MP, et al. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995; 221(6): 706-718.
    31. Lu C, Shen Q, DuPré E, et al. cFos is critical for MCF-7 breast cancer cell growth. Oncogene 2005; 24(43): 6516-6524.
    32. Hop HT, Arayan LT, Huy TX, et al. The key role of c-Fos for immune regulation and bacterial dissemination in Brucella infected macrophage. Front Cell Infect Microbiol 2018; 8: doi: 10.3389/fcimb.2018.00287.
    33. Ren HY, Sun LL, Li HY, et al. Prognostic significance of serum alkaline phosphatase level in osteosarcoma: a meta-analysis of published data. BioMed Res Int 2015; 2015: 160835 doi: 10.1155/2015/160835.
    34. Pautke C, Schieker M, Tischer T, et al. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res 2004; 24(6): 3743-3748.
    35. Ali NN, Harrison MA, Rowe J, et al. Spectrum of osteoblastic differentiation in new cell lines derived from spontaneous murine osteosarcomas. Bone 1993; 14(6): 847-858.
    36. Xiao Y, Lu J, Chang W, et al. Dynamic serum alkaline phosphatase is an indicator of overall survival in pancreatic cancer. BMC cancer 2019; 19: 785. doi:10.1186/s12885-019-6004-7.
    37. Kim JM, Kwon CHD, Joh JW, et al. The effect of alkaline phosphatase and intrahepatic metastases in large hepatocellular carcinoma. World J Surg Oncol 2013; 11: 40. doi: 10.1186/1477-7819-11-40.
    38. Wang Y, Xu H, Zhu B, et al. Systematic identification of the key candidate genes in breast cancer stroma. Cell Mol Biol lett 2018; 23: 44. doi: 10.1186/s11658-018-0110-4.
    39. Willis CM, Klüppel M. Chondroitin sulfate-E is a negative regulator of a pro-tumorigenic Wnt/beta-catenin-Collagen 1 axis in breast cancer cells. PLoS One 2014; 9(8): e103966. doi: 10.1371/journal.pone. 0103966.
    40. Feng YX, Sokol ES, Del Vecchio CA, et al. Epithelial-to-mesenchymal transition activates PERK–eIF2α and sensitizes cells to endoplasmic reticulum stress. Cancer Discov 2014; 4(6): 702-715.
    41. Guo W, Keckesova Z, Donaher JL, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012; 148(5): 1015-1028.
    42. Limia CM, Sauzay C, Urra H, et al. Emerging roles of the endoplasmic reticulum associated unfolded protein response in cancer cell migration and invasion. Cancers (Basel) 2019; 11(5): 631. doi:10.3390/cancers11050631.
    43. Liu S, Liao G, Li G. Regulatory effects of COL1A1 on apoptosis induced by radiation in cervical cancer cells. Cancer Cell Int 2017; 17: 73. doi: 10.1186/s12935-017-0443-5.
    44. Lin X, Shang X, Manorek G, et al. Regulation of the epithelial-mesenchymal transition by claudin-3 and claudin-4. PloS One 2013; 8(6): e67496. doi: 10.1371/journal.pone.0067496.
    45. Muhammad N, Bhattacharya S, Steele R, et al. Involvement of c-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma. Clin Cancer Res 2017; 23(12): 3120-3128.
    46. Rao SR, Snaith AE, Marino D, et al. Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer. Br J Cancer 2017; 116(2): 227-236.
Veterinary Research Forum
Volume 13, Issue 3
Summer 2022
Pages 393-401

  • Receive Date 24 February 2021
  • Revise Date 24 April 2021
  • Accept Date 08 May 2021

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us